Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT00536614 Completed - Pancreatic Cancer Clinical Trials

Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer

SPaCe-01
Start date: May 2005
Phase: Phase 2
Study type: Interventional

This is multicenter, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Primary objective: objective response rate. Secondary objectives: safety, time to disease progression, median duration of response, time to treatment failure, overall survival time, correlation between bio-pathological characterization (EGFR, akt, MAPks) objective response and survival

NCT ID: NCT00534001 Completed - Lung Cancer Clinical Trials

Bupropion in Helping Adults Stop Smoking

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking. PURPOSE: This randomized phase II trial is studying how well bupropion works in helping adults stop smoking.

NCT ID: NCT00529984 Completed - Breast Cancer Clinical Trials

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

CEA(6D)VRP
Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES 1. The primary objective of this protocol is to determine the safety of immunization with CEA(6D) VRP in patients with advanced or metastatic CEA expressing malignancies. 2. The secondary objectives are to evaluate CEA-specific immune response to the immunizations and obtain preliminary data on response rate.

NCT ID: NCT00521404 Completed - Pancreatic Cancer Clinical Trials

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

Start date: August 15, 2007
Phase: Phase 2
Study type: Interventional

Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.

NCT ID: NCT00515866 Completed - Clinical trials for Pancreatic Neoplasms

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.

NCT ID: NCT00514163 Completed - Pancreatic Cancer Clinical Trials

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare tumor response rate of the test arm(gemcitabine+S-1) with the control arm(gemcitabine alone) in patients with unresectable pancreatic cancer

NCT ID: NCT00511264 Completed - Pancreatic Cancer Clinical Trials

Laparoscopic Ultrasound Guided Tissue Sampling in Patients With Cancer of the Upper Gastrointestinal Tract

Start date: May 2007
Phase: N/A
Study type: Observational

Laparoscopic Ultrasound (LUS) is an important part of the pre-treatment evaluation of patients with upper gastrointestinal tract cancer (esophageal, gastric, pancreatic and liver cancer). When a suspect lesion is visualized during LUS a biopsy should be provided in order to differentiate between benign and malignant lesions. A new system for LUS guided biopsy has been developed, but how often these biopsies are clinically relevant (i.e. changing patient management)and how reliable are these biopsies are unknown. The study hypothesis is that LUS guided biopsies are accurate and clinically relevant in the pre-treatment evaluation of patients with upper gastrointestinal tract cancer.

NCT ID: NCT00504998 Completed - Pancreatic Cancer Clinical Trials

Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer

Start date: July 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.

NCT ID: NCT00501176 Completed - Pancreas Cancer Clinical Trials

Preoperative Stent Study

Start date: December 2006
Phase: N/A
Study type: Interventional

Randomized study comparing the effect of plastic stents to that of expandable metal stents as pre-operative drainage of the bile ducts prior to Whipple operation.

NCT ID: NCT00500968 Completed - Pancreas Cancer Clinical Trials

Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail

Start date: November 2006
Phase: N/A
Study type: Interventional

Randomized study assessing the effect of transpapillary pancreas duct stent in resection of the pancreatic tail.